Ari Vanderwalde
Director
George Clinical
Australia
Biography
Dr Ari VanderWalde is an internationally-recognized cancer researcher, Dr. VanderWalde holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Research and Assistant Professor, Hematology/Oncology. Dr. VanderWalde previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma. As an expert in melanoma, Dr. VanderWalde has collaborated with some of the nation’s thought leaders and participated on advisory boards with top experts in the field.
Research Interest
Resaerch interest on Business development
